Stanisław K.
- Country
- Poland
- Department
- Oddział Chirurgii Ogólnej i Leczenia Niewydolności Przewodu Pokarmowego
Research Overview
- Evaluation of Long-term Safety and Tolerability of Apraglutide in Patients with Short Bowel Syndrome-Intestinal Failure
- Long-Term Safety and Efficacy Evaluation of Glepaglutide in Patients with Short Bowel Syndrome: A Phase 3 Double-Blind Extension Trial
- Long-term Safety and Efficacy Evaluation of Glepaglutide in Adult Patients with Short Bowel Syndrome: A 104-Week Phase 3 Extension Study
Data & Insights
Has run more than one trial at 22 of 60 partner sites.
Specializations
Digestive Surgery and Intestinal Failure
Clinical research activity includes short bowel syndrome, short bowel syndrome-associated intestinal failure, and postoperative support for patients with complex gastrointestinal loss of function. The therapeutic focus also extends to intestinal rehabilitation and long-term management of malabsorptive conditions.
- Short bowel syndrome
- Short bowel syndrome-associated intestinal failure
- Intestinal failure
- Postoperative gastrointestinal dysfunction
Work in this area reflects interest in restoring gastrointestinal function and improving treatment options for patients with severe digestive tract insufficiency.
Gastrointestinal and Hepatobiliary Oncology
The oncologic landscape includes colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, and biliary tract cancer, with additional involvement in hepatocellular carcinoma and esophageal cancer. Research interest also covers advanced and metastatic disease settings across the digestive system.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic ductal adenocarcinoma
- Hepatocellular carcinoma
This domain is closely linked to therapeutic development for refractory gastrointestinal malignancies and other hard-to-treat solid tumors.
Breast Cancer and Endocrine-Driven Malignancies
Research involvement is broad in hormone receptor-positive, HER2-negative breast cancer, triple-negative breast cancer, and HER2-positive breast cancer, including early-stage, locally advanced, and metastatic presentations. The clinical focus also includes endocrine-sensitive disease and recurrence prevention strategies.
- Hormone receptor-positive breast cancer
- Triple-negative breast cancer
- HER2-positive breast cancer
- Early and metastatic breast cancer
Therapeutic interests extend to precision approaches for biomarker-defined breast cancer subtypes and treatment-resistant disease.
Thoracic Oncology and Targeted Lung Cancer Therapy
Clinical trial activity includes non-small cell lung cancer, small cell lung cancer, EGFR-mutated lung cancer, ALK-altered disease, RET fusion-positive tumors, and KRAS G12C-mutated malignancies. The portfolio also covers locally advanced, metastatic, and resectable thoracic tumors.
- Non-small cell lung cancer
- Small cell lung cancer
- EGFR-mutated lung cancer
- KRAS G12C-mutated lung cancer
These studies reflect a strong therapeutic emphasis on biomarker-directed treatment in lung malignancies and other thoracic cancers.
Hematologic Malignancies and Cellular Immunotherapy
Research interests encompass diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, classical Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The scope also includes relapsed and refractory lymphoid malignancies and advanced B-cell neoplasms.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Classical Hodgkin lymphoma
- Multiple myeloma
Therapeutic activity in this area supports innovation in immune-based and targeted strategies for difficult hematologic cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.